For the year ending 2025-12-31, MREO has $45,917K in assets. $5,001K in debts. $40,992K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 40,992 | |||
| Prepaid expenses and other current assets | 2,531 | |||
| Research and development incentives receivables | 1,497 | |||
| Total current assets | 45,020 | |||
| Property and equipment, at cost | 1,222 | |||
| Less accumulated depreciation | 1,085 | |||
| Property and equipment, net | 137 | |||
| Operating lease right-of-use assets, net | 244 | |||
| Intangible assets, net | 516 | |||
| Total assets | 45,917 | |||
| Accounts payable | 1,333 | |||
| Accrued expenses | 2,026 | |||
| Convertible loan notes - current | 0 | |||
| Operating lease liabilities - current | 202 | |||
| Other current liabilities | 741 | |||
| Total current liabilities | 4,302 | |||
| Warrant liabilities - non current | 38 | |||
| Operating lease liabilities- non current | 0 | |||
| Other non-current liabilities | 661 | |||
| Total liabilities | 5,001 | |||
| Ordinary shares, par value 0.003 per share 795,658,504 shares issued at december 31, 2025 (december 31, 2024 775,728,034) | 3,135 | |||
| Additional paid-in capital | 549,622 | |||
| Accumulated deficit | -501,018 | |||
| Accumulated other comprehensive loss | -10,823 | |||
| Total shareholders' equity | 40,916 | |||
| Total liabilities and shareholders' equity | 45,917 | |||
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (MREO)